Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
Benjamin E. Peterson, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 6
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Samuel Sherratt, Peter Libby, Matthew J. Budoff, et al.
Current Atherosclerosis Reports (2022) Vol. 25, Iss. 1, pp. 1-17
Open Access | Times Cited: 77
Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence
Salman Zahoor Bhat, Sudipa Sarkar, Duha Zaffar, et al.
Current Cardiology Reports (2023) Vol. 25, Iss. 2, pp. 51-65
Closed Access | Times Cited: 32
Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review
Stefan Zivkovic, Gorica Marić, Nataša Cvetinovic, et al.
Nutrients (2023) Vol. 15, Iss. 6, pp. 1517-1517
Open Access | Times Cited: 29
Do patients benefit from omega-3 fatty acids?
Samuel Sherratt, R. Preston Mason, Peter Libby, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 18, pp. 2884-2901
Open Access | Times Cited: 26
Omega-3 fatty acids for cardiovascular event lowering
Gurleen Kaur, R. Preston Mason, Philippe Gabríel Steg, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 8, pp. 1005-1014
Open Access | Times Cited: 15
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial
Rahul Aggarwal, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Journal of the American Heart Association (2025)
Open Access | Times Cited: 1
Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention
Seung‐Jun Lee, Jae Hong Joo, Sohee Park, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 5, pp. 401-410
Open Access | Times Cited: 20
Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT
Mark Rabbat, Suvasini Lakshmanan, Mina M. Benjamin, et al.
European Heart Journal - Cardiovascular Imaging (2023) Vol. 24, Iss. 7, pp. 866-873
Open Access | Times Cited: 19
Bleeding Risk in Patients Receiving Omega‐3 Polyunsaturated Fatty Acids: A Systematic Review and Meta‐Analysis of Randomized Clinical Trials
Mustafa Javaid, Kadhim Kadhim, Bilal Bawamia, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 10
Open Access | Times Cited: 8
A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes
Samuel Sherratt, Peter Libby, Deepak L. Bhatt, et al.
Prostaglandins Leukotrienes and Essential Fatty Acids (2022) Vol. 182, pp. 102450-102450
Open Access | Times Cited: 26
Omega-3-fatty acids: Do they prevent cardiovascular disease?
R. Preston Mason, Samuel Sherratt, Robert H. Eckel
Best Practice & Research Clinical Endocrinology & Metabolism (2022) Vol. 37, Iss. 3, pp. 101681-101681
Open Access | Times Cited: 21
Effects of omega-3, omega-6, and total dietary polyunsaturated fatty acid supplementation in patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis
Siqi Luo, Hongmei Hou, Yongjin Wang, et al.
Food & Function (2023) Vol. 15, Iss. 3, pp. 1208-1222
Closed Access | Times Cited: 11
Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis
Nathália Mendes Machado, Maria Júlia Ribeiro de Oliveira, Karina Quesada, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 601-601
Open Access
The effectiveness of the current lipid-lowering therapy for refractory dyslipidaemia in patients with coronary artery disease: the price of “the lower, the better” – results of a survey by Japanese cardiologists
Satoru Hashimoto, Yoshihiro Motozawa, Toshiki Mano
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
Michael Miller, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2022) Vol. 9, Iss. 2, pp. 129-137
Open Access | Times Cited: 16
Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease
Michael Miller
Current Opinion in Cardiology (2024)
Open Access | Times Cited: 3
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
Jessica Huston, Hannah Schaffner, Alyssa Cox, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 4, pp. 393-406
Open Access | Times Cited: 7
Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials
Chang‐Jiang Deng, Yan Ju, Ying-Ying Zheng, et al.
BMJ Open (2023) Vol. 13, Iss. 11, pp. e070827-e070827
Open Access | Times Cited: 7
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT
Prakriti Gaba, Deepak L. Bhatt, R. Preston Mason, et al.
Journal of clinical lipidology (2022) Vol. 16, Iss. 4, pp. 389-402
Open Access | Times Cited: 12
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn
Michael Miller, Deepak L. Bhatt, Eliot A. Brinton, et al.
European Heart Journal Open (2023) Vol. 3, Iss. 6
Open Access | Times Cited: 7
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial
Ehab Bakbak, Aishwarya Krishnaraj, Deepak L. Bhatt, et al.
Med (2024) Vol. 5, Iss. 7, pp. 718-734.e4
Closed Access | Times Cited: 2
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
P.M. Burger, Deepak L. Bhatt, Jannick A N Dorresteijn, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2024) Vol. 10, Iss. 6, pp. 488-499
Open Access | Times Cited: 2
Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial
Jong‐Il Park, Seung‐Jun Lee, Bum‐Kee Hong, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101933-101933
Open Access | Times Cited: 6
Effect of Intensive Lipid-Lowering Therapy on Coronary Plaque Stabilization Derived from Optical Coherence Tomography: a Meta-analysis and Meta-regression
Sen Liu, Jixin Hou, Jindong Wan, et al.
Cardiovascular Drugs and Therapy (2023)
Closed Access | Times Cited: 5
DHA, RvD1, RvD5, and MaR1 reduce human coronary arteries contractions induced by PGE2
Amel Bouhadoun, Hasanga D. Manikpurage, Catherine Deschildre, et al.
Prostaglandins & Other Lipid Mediators (2022) Vol. 165, pp. 106700-106700
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top